VitalTransformation

In our latest episode of the Vital Health Podcast, host Duane Schulthess speaks with two Vital Transformation (@VitalTransform) colleagues on biopharma pricing policy, market access, and innovation risk: - Gwen O'Loughlin: Research Partner at Vital Transformation (@VitalTransform) - Harry P. Bowen: Consulting Economist at Vital Transformation (@VitalTransform) They discuss what our new MFN pricing modeling suggests about drug viability and how IRA incentives appear to be reshaping oncology and orphan drug development. They also examine why Medicare Advantage and commercial coverage can create administrative friction and delays compared with traditional Medicare, how 340B opacity and consolidation affect the value chain, and what these pressures could mean for insurance premiums, investment, and future innovation. Watch the full episode here: youtube.com/watch?v=prAQf8… #VitalHealthPodcast #HealthPolicy #Biopharma #MarketAccess @VitalTransform

In our recent episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with three guests on accelerated patient access to cancer medicines in Europe and the APACE framework: - Martina Garau, Director at Office of Health Economics (@OHENews) - Bettina Ryll (@BettinaRyll), Founder at MPNEurope (@MPNEurope) - Kathleen Grieve, Director - European Public Policy, Access, Pricing and Affordability Lead at MSD Europe (@MSDInvents) Watch the full episode here: youtube.com/watch?v=TK3nIu… #VitalHealthPodcast #ISPOR #ISPOREurope #Cancer #Oncology #AccessToMedicines #HTA #HealthPolicy @ISPORorg

In our recent episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with three guests on accelerated patient access to cancer medicines in Europe and the APACE framework: - Martina Garau, Director at Office of Health Economics (@OHENews) - Bettina Ryll (@BettinaRyll), Founder at MPNEurope (@MPNEurope) - Kathleen Grieve, Director - European Public Policy, Access, Pricing and Affordability Lead at MSD Europe (@MSDInvents) Watch the full episode here: youtube.com/watch?v=TK3nIu… #VitalHealthPodcast #ISPOR #ISPOREurope #Cancer #Oncology #AccessToMedicines #HTA #HealthPolicy @ISPORorg

In our recent episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with two guests on reimbursement-facing evidence for accelerated oncology approvals: - Anja Schiel, Senior Advisor at Norwegian Medical Products Agency - Niklas Hedberg, Chief Pharmacist at The Dental and Pharmaceutical Benefits Agency, TLV (@TLV_nyheter) Watch the full episode here: youtube.com/watch?v=UYzwTW… #VitalHealthPodcast #ISPOR #ISPOREurope #HTA #Oncology #RealWorldEvidence #HealthPolicy @ISPORorg

In our recent episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with three guests on accelerated patient access to cancer medicines in Europe: - Martina Garau (@martinagarau09), Director at Office of Health Economics (@OHENews) - Bettina Ryll (@BettinaRyll), Founder at MPNEurope (@MPNEurope) - Kathleen Grieve (@Grieve9Kathleen), Director - European Public Policy Access, Pricing and Affordability Policy Lead at MSD Europe (@MSDInvents) Watch the full episode here: youtube.com/watch?v=TK3nIu… #VitalHealthPodcast #ISPOR #ISPOREurope #CancerCare #PatientAccess #HTA #HealthPolicy #Biopharma @ISPORorg

Most Favored Nation (MFN) reference pricing uses prices in other countries as a benchmark for U.S. medicines covered under Medicare Parts B and D. Large companies can negotiate separate deals, while smaller companies may not have the resources to do so. In our recent episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with Tim Scott, President & CEO at Biocom California (@Biocom), about Most Favored Nation (MFN) reference pricing and what it could mean for investment in new medicines. Watch the full episode here: youtu.be/TVjnNnRwBZY #VitalHealthPodcast #MFN #Medicare #HealthPolicy #Biopharma

China is becoming a major player in U.S.-facing clinical research, with a rise in trials registered with the FDA. In our recent episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with Tim Scott, President and CEO of Biocom California (@Biocom), about China’s growing role in global drug development, venture capital pressure, MFN reference pricing, IRA incentives, rare disease investment risk, and the future of California’s life science ecosystem. Watch the full episode here: youtu.be/TVjnNnRwBZY #VitalHealthPodcast #Biotech #ClinicalTrials #LifeScience #Innovation #IntellectualProperty

Biocom’s earliest policy work began with access to water for biotech operations. During a Southern California drought, periodic water shutoffs threatened lab work and pushed companies to coordinate municipal advocacy. In our recent episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with Tim Scott, President and CEO at Biocom (@Biocom), about California’s life science ecosystem, research and venture networks, and federal policy pressures on medicine pricing. Watch the full episode here: youtu.be/TVjnNnRwBZY #VitalHealthPodcast #LifeSciences #Biotech #Biopharma #HealthPolicy #VentureCapital #MedicinePricing

In our most recent episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with Tim Scott, President & CEO of Biocom California (@Biocom), to discuss how California’s life sciences ecosystem became a global innovation engine, why the state’s research and venture networks matter, and how policy headwinds reshape investment. Key Topics: - Biocom Origins: Municipal policy roots, industry advocacy, ecosystem evolution across California. - Innovation Network: University and research density, regional clusters, talent, and collaboration effects. - Capital Pathway: NIH and NSF support, SBIR and STTR bridges, venture appetite, and liquidity. - MFN and IRA: Pill penalty incentives, orphan exemption stakes, Medicare exposure, and VC pullback. - Next-Gen Development: AI-enabled discovery, faster trial enrollment, digital twins, and regulator openness. Watch the full podcast here: youtube.com/watch?v=TVjnNn… Opinions expressed are those of the speakers. #VitalHealthPodcast #MFN #IRA #PillPenalty #Biotech #Biopharma

In our recent episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with two guests on evidence standards for accelerated oncology approvals and reimbursement decisions: - Anja Schiel, Senior Advisor at Norwegian Medical Products Agency - Niklas Hedberg, Chief Pharmacist at The Dental and Pharmaceutical Benefits Agency (TLV; @TLV_nyheter) Watch the full episode here: youtube.com/watch?v=UYzwTW… #VitalHealthPodcast #ISPOR #ISPOREurope #HTA #EMA #RWE #HealthPolicy @ISPORorg

Some public debate credits NIH with developing medicines, but NIH’s role is funding research and transferring technology so universities and companies can build products. In our most recent episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with two guests to clarify that distinction and explore NIH technology transfer, patent signals, and march-in rights: - Mark L. Rohrbaugh, Former Director of Technology Transfer and Innovation Policy at The National Institutes of Health (@NIH), IP Consultant at Vital Transformation (@VitalTransform) - Gwen O'Loughlin, Research Partner at Vital Transformation (@VitalTransform) Watch the full episode here: omny.fm/shows/vital-he… #VitalHealthPodcast #NIH #TechnologyTransfer #Patents #HealthPolicy

In this episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) examines how NIH-funded research fits into the U.S. innovation and IP ecosystem, and why today’s political rhetoric about “government-developed drugs” often misses how commercialization actually happens. Featuring expert perspectives on NIH technology transfer and drug IP from: - Mark Rohrbaugh: Former Director of Technology Transfer and Innovation Policy at the National Institutes of Health (@NIH), IP Consultant at Vital Transformation (@VitalTransform) - Gwen O’Loughlin: Research Partner at Vital Transformation (@VitalTransform) Listen to the full episode here: omny.fm/shows/vital-he… #VitalHealthPodcast

In our recent episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with two experts on evidence standards for early oncology access at ISPOR Europe 2025 in Glasgow, Scotland: - Oriana Ciani (@OrianaCiani), Associate Professor of Practice at SDA Bocconi School of Management (@sdabocconi) - Denis Lacombe, Director General at EORTC - European Organisation for Research and Treatment of Cancer (@EORTC) Watch the full episode here: youtube.com/watch?v=q5J_hu… #VitalHealthPodcast #ISPOREurope2025 #Oncology #HTA #EMA @ISPOROrg

In our recent episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with two experts on evidence standards for early oncology access at ISPOR Europe 2025 in Glasgow, Scotland: - Oriana Ciani (@OrianaCiani), Associate Professor of Practice at SDA Bocconi School of Management (@sdabocconi) - Denis Lacombe, Director General at EORTC - European Organisation for Research and Treatment of Cancer (@EORTC) Watch the full episode here: youtube.com/watch?v=q5J_hu… #VitalHealthPodcast #ISPOREurope2025 #Oncology #HTA #EMA @ISPOROrg

In our latest episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with two experts on evidence standards for early oncology access at ISPOR Europe 2025 in Glasgow, Scotland: - Oriana Ciani (@OrianaCiani): Associate Professor of Practice, SDA Bocconi School of Management (@sdabocconi) - Denis Lacombe: Director General, European Organisation for Research and Treatment of Cancer (@EORTC) Watch the full episode here: youtu.be/q5J_huXMTtw #ISPOREurope2025 @ISPORorg

In our recent episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with two guests on trial generalizability and reimbursement evidence for accelerated oncology approvals: - Anja Schiel, Senior Advisor at Norwegian Medical Products Agency - Niklas Hedberg, Chief Pharmacist at The Dental and Pharmaceutical Benefits Agency, TLV (@TLV_nyheter) Watch the full episode here: youtube.com/watch?v=UYzwTW… #VitalHealthPodcast #HTA #EMA #RWE #HealthPolicy #ISPOR #ISPOREurope #Oncology @ISPORorg

National reimbursement decisions require a careful balance between evidence uncertainty and clinical urgency. When disease worsens irreversibly, systems may accept more financial risk while evidence matures. In our recent episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with two guests on reimbursement-facing evidence questions for accelerated oncology approvals: - Anja Schiel, Senior Advisor at Norwegian Medical Products Agency - Niklas Hedberg, Chief Pharmacist at The Dental and Pharmaceutical Benefits Agency (TLV, @TLV_nyheter) Watch the full episode here: youtu.be/UYzwTWm91-8 #VitalHealthPodcast #ISPOREurope2025 #HTA #EMA #RWE #HealthPolicy #Oncology @ISPORorg

In this episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with two experts on reimbursement-facing evidence questions for accelerated oncology approvals at ISPOR Europe 2025 in Glasgow, Scotland: - Anja Schiel: Senior Advisor, Norwegian Medical Products Agency - Niklas Hedberg: Chief Pharmacist at The Dental and Pharmaceutical Benefits Agency (TLV, @TLV_nyheter) They unpack why results that are strong inside a clinical trial can be harder to apply to real-world national populations, how decision-makers weigh patient-relevant outcomes and uncertainty at the time of access decisions, and what risk management can look like when early approvals require follow-up evidence and potential reassessment. Watch the full episode here: youtu.be/UYzwTWm91-8 #ISPOREurope2025 @ISPORorg

In our recent episode of the Vital Health Podcast, host Duane Schulthess (@DuaneSchulthess) speaks with three guests on accelerated patient access to cancer medicines in Europe and the APACE framework: - Martina Garau, Director at Office of Health Economics (@OHENews) - Bettina Ryll (@BettinaRyll), Founder at MPNEurope (@MPNEurope) - Kathleen Grieve, Director - European Public Policy, Access, Pricing and Affordability Lead at MSD Europe (@MSDInvents) Watch the full episode here: youtube.com/watch?v=TK3nIu… Learn more about the APACE framework: ohe.org/wp-content/upl… #VitalHealthPodcast #ISPOR #ISPOREurope #Cancer #Oncology #AccessToMedicines #HTA #HealthPolicy @ISPORorg